Cargando…

Structure‐Based Evolution of G Protein‐Biased μ‐Opioid Receptor Agonists

The μ‐opioid receptor (μOR) is the major target for opioid analgesics. Activation of μOR initiates signaling through G protein pathways as well as through β‐arrestin recruitment. μOR agonists that are biased towards G protein signaling pathways demonstrate diminished side effects. PZM21, discovered...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haoqing, Hetzer, Florian, Huang, Weijiao, Qu, Qianhui, Meyerowitz, Justin, Kaindl, Jonas, Hübner, Harald, Skiniotis, Georgios, Kobilka, Brian K., Gmeiner, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322534/
https://www.ncbi.nlm.nih.gov/pubmed/35385593
http://dx.doi.org/10.1002/anie.202200269
Descripción
Sumario:The μ‐opioid receptor (μOR) is the major target for opioid analgesics. Activation of μOR initiates signaling through G protein pathways as well as through β‐arrestin recruitment. μOR agonists that are biased towards G protein signaling pathways demonstrate diminished side effects. PZM21, discovered by computational docking, is a G protein biased μOR agonist. Here we report the cryoEM structure of PZM21 bound μOR in complex with G(i) protein. Structure‐based evolution led to multiple PZM21 analogs with more pronounced G(i) protein bias and increased lipophilicity to improve CNS penetration. Among them, FH210 shows extremely low potency and efficacy for arrestin recruitment. We further determined the cryoEM structure of FH210 bound to μOR in complex with G(i) protein and confirmed its expected binding pose. The structural and pharmacological studies reveal a potential mechanism to reduce β‐arrestin recruitment by the μOR, and hold promise for developing next‐generation analgesics with fewer adverse effects.